Key result
Bioabsorbable venous closure cuts median ambulation time by ~60 minutes compared with figure-of-eight sutures.
Why the study?
Optimizing femoral venous access management is increasingly important for safe and accelerated recovery pathways after AF catheter ablation, motivating comparison of a bioabsorbable venous vascular closure system against a conventional figure-of-eight suture following single-shot PVI.
Does femoral venous closure using a bioabsorbable venous vascular closure system reduce time to ambulation and periprocedural adverse events compared with conventional figure-of-eight suture in patients undergoing single-shot pulmonary vein isolation?
RCT (n=100)
1:1 ratio
Yes
Does femoral venous closure using a bioabsorbable venous vascular closure system reduce time to ambulation and periprocedural adverse events compared with conventional figure-of-eight suture in patients undergoing single-shot pulmonary vein isolation?
Using a bioabsorbable venous vascular closure system after single-shot atrial fibrillation ablation significantly accelerates time to ambulation and discharge eligibility while reducing minor vascular access complications compared with conventional figure-of-eight sutures.
Answers are grounded in this paper and cite their sources.
Supports earlier ambulation after catheterization; confirms VCS benefits versus F8 sutures in an RCT.
AIMS: Optimization of femoral venous access management has become increasingly important as catheter ablation of atrial fibrillation (AF) continues to evolve towards greater safety with accelerated recovery pathways. We evaluated the efficacy and safety of a bioabsorbable venous vascular closure system (VCS) compared with a conventional figure-of-eight (F8) suture and manual compression following contemporary single-shot pulmonary vein isolation (PVI). METHODS AND RESULTS: VASC-AF was a prospective, multicentre, randomized controlled trial performed at three German electrophysiology centres. One hundred consecutive patients undergoing single-shot PVI were randomized in a 1:1 ratio to femoral venous closure using the VASCADE MVP VCS; (n=50) or conventional F8 suture (n=50). The primary efficacy endpoint was time to ambulation. The primary safety endpoint comprised major periprocedural adverse events requiring medical intervention before hospital discharge.Baseline characteristics and procedural variables were comparable between study groups. Median time to ambulation was significantly shorter following vascular closure with VCS compared with F8 sutures (120 [120-150] vs. 180 [180-240] min; P=0.015). Likewise, time to haemostasis (0.5 [0.5-2] vs. 1 [1-2] min; P=0.021) and time to discharge eligibility (2.5 [2.1-3.0] vs. 4.0 [3.0-5.0] h; P=0.019) were significantly reduced.Major adverse events occurred infrequently and did not differ significantly between groups. In contrast, vascular closure using VCS significantly reduced minor vascular access complications (6% vs. 26%; P=0.006), groin pain, and patient discomfort while improving overall post-procedural satisfaction. CONCLUSION: Among patients undergoing contemporary single-shot AF ablation, use of a bioabsorbable VCS significantly accelerated post-procedural recovery while maintaining a comparable major safety profile. Reduced access-site complications and improved patient-reported outcomes support VCS as an important component of enhanced recovery pathways following AF ablation especially in an ambulatory or Same-Day Discharge setting.
No takes yet. Share an insight, caveat, or question.
Heeger et al. (2026) conducted an RCT in Atrial fibrillation undergoing single-shot pulmonary vein isolation (n=100). Bioabsorbable venous vascular closure system (VASCADE MVP VCS) vs. Conventional figure-of-eight (F8) suture and manual compression was evaluated on Time to ambulation (p=0.015). Femoral venous closure with a bioabsorbable vascular closure system shortened median time to ambulation compared with figure-of-eight sutures.
Synapse has enriched 10 related papers. Consider them for comparative context: